Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Vanda Pharmaceuticals Trading Down 2.8 %

Shares of NASDAQ:VNDA opened at $5.65 on Wednesday. The company has a market capitalization of $328.83 million, a PE ratio of -70.63 and a beta of 0.71. Vanda Pharmaceuticals has a twelve month low of $3.30 and a twelve month high of $6.75. The firm has a 50 day simple moving average of $5.38 and a 200-day simple moving average of $4.54.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.12). The company had revenue of $47.46 million for the quarter, compared to analysts’ expectations of $48.50 million. Vanda Pharmaceuticals had a negative return on equity of 0.90% and a negative net margin of 2.75%.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of institutional investors have recently modified their holdings of VNDA. China Universal Asset Management Co. Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 5,186 shares during the period. SageView Advisory Group LLC acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at $34,000. Raymond James & Associates acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at $42,000. Mackenzie Financial Corp acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at $46,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $52,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.